COMP <GO>
ANAB vs PCRX // EV/EBITDA & P/E VALUATION
AnaptysBio Inc. (NASDAQ) VS. Pacira BioSciences Inc. (NASDAQ) • 15-METRIC TALLY: ANAB 4
— PCRX 5
▲ EV/EBITDA & P/E VALUATION LEADER: ANAB
LAST: $48.64 (-3.68%) • MKT CAP: $1.44B
valuation
5.7x
LAST: $36.39 (0.00%) • MKT CAP: $1.45B
valuation
51.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANAB VS. PCRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANAB | PCRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 79.40% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 1.70% | +83.30 | ANAB | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 5.7x | 51.6x | -45.90 | ANAB | /valuation <GO> |
| Free Cash Flow Yield | 1.36% | 9.42% | -8.06 | PCRX | /fcf-yield <GO> |
| Operating Margin | 75.00% | 2.60% | +72.40 | ANAB | /operating-margins <GO> |
| Net Profit Margin | -5.60% | 1.00% | -6.60 | PCRX | /net-margins <GO> |
| Revenue Growth (YoY) | 157.00% | 3.60% | +153.40 | ANAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | PCRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 83.2 | -36.48 | PCRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.44B | $1.45B | -$10.4M | PCRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANAB REV | PCRX REV | ANAB GROSS % | PCRX GROSS % | ANAB FCF | PCRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $234.6M | $726.4M | — | 79.4% | $19.6M | $136.7M |
| FY 2024 | $91.3M | $701.0M | — | 75.7% | -$135.7M | $178.8M |
| FY 2023 | $17.2M | $675.0M | — | — | -$120.8M | $154.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANAB // BETA —
PCRX // BETA —